Sophie Blondel is CEO and co-founder of FoxBio, a biotech company advancing CAR-Treg-based ex-vivo gene therapies for chronic inflammation. With over 15 years of experience in the gene and cell therapy space, she has overseen non-clinical, pharmaceutical and clinical development, regulatory strategy, and international partnerships from discovery to early clinical trials. She is an expert in biotech structuring, innovation financing, and translational science.

At Sangamo Therapeutics, she led the development of ex vivo gene therapy programs in gastro and neurology. She also managed complex CMC strategies and regulatory interactions with FDA and EMA. Prior to this, Sophie held various leadership roles at YposKesi and I-Stem, contributing to pre-clinical and clinical dévelopment of cell & gene therapies, to public fundraising, R&D and  cGMPfacilities creation and platform development. Sophie is also founder of Cell and Gene Therapy Consulting. She holds a PhD in Cell Biology and a PharmD from Université Paris Cité, and completed executive training at HEC Paris.